

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Sirnaomics Ltd.**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2257)**

**APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Edward Yongxiang Wang (“**Dr. Wang**”) has been appointed as an executive Director with effect from May 10, 2024.

The biographical details of Dr. Wang are set out as follows:

Dr. Wang, aged 71, is the Chief Production Officer of the Group. Dr. Wang joined the Group in August 2020. Prior to joining the Group, Dr. Wang served as (i) the senior scientist in the National Cancer Institute — Biopharmaceutical development program in the U.S. from January 2001 to December 2004; (ii) the technology director of Charter Medical Ltd. from January 2005 to December 2006; (iii) the deputy director of engineering in the US AERAS Global Tuberculosis Vaccine Foundation R&D Base (a non-profit organization affiliated with the Bill & Melinda Gates Foundation) from May 2007 to October 2011; (iv) the technology consultant of Parexel International in Ben Venue Laboratory of Boehringer Ingelheim from October 2011 to October 2012; (v) the vice president of technical operations at Wuxi Biological Base of WuXi AppTec Co., Ltd., a company listed on The Stock Exchange of Hong Kong Limited (stock code: 2359), from October 2012 to February 2014; (vi) the director of vaccine production in Newlink Genetics Inc. for a special project to fight the Ebola Epidemic from August 2014 to June 2016; and (vii) the deputy general manager at Shanghai Furen Medicine R&D Co., Ltd. (上海輔仁醫藥研發有限公司) from October 2016 to June 2018.

Dr. Wang received his bachelor’s degree of biophysics in University of Science and Technology of China in the PRC in November 1976, his master’s degree of biochemistry in Tokyo Institute of Technology in Japan in September 1983, and his doctoral degree of technology at the Department of Chemical Engineering in the Faculty of Engineering and Materials Science at the Helsinki University of Technology in Finland in December 1995.

The Board considered and accepted the recommendation from the nomination committee of the Company to the appointment of Dr. Wang as an executive Director, after reviewing his scientific credentials, professional experience and contributions to the Group.

As at the date of this announcement, within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), Dr. Wang was deemed to be interested in (i) an aggregate of 313,326 shares of the Company (the “**Shares**”) and underlying Shares; (ii) an aggregate of 150,000 underlying shares of RNAimmune, Inc., a controlled subsidiary of the Company; and (iii) an aggregate of 250,000 shares of EDIRNA Inc., a non-wholly owned subsidiary of the Company.

Dr. Wang has entered into a service contract (the “**Service Contract**”) with the Company in relation to his appointment as an executive Director for a term of three years commencing from May 10, 2024, which may be terminated by not less than 3 months’ notice in writing served by either party on the other and is subject to termination provisions therein and provisions on retirement by rotation of Directors as set out in the fourth amended and restated articles of association of the Company. Pursuant to the Service Contract, Dr. Wang is entitled to nil annual emolument as an executive Director. Dr. Wang has previously entered into an employment contract with Sirnaomics, Inc., a wholly owned subsidiary of the Company, in relation to his employment as Chief Production Officer of the Group, pursuant to which Dr. Wang is entitled to an annual emolument of US\$167,500. The emoluments of Dr. Wang are determined, with delegated responsibility, by the remuneration committee of the Company with reference to his background, qualifications, experience, level of responsibilities undertaken with the Group and prevailing market conditions, and will be subject to annual review by the remuneration committee of the Company and the Board.

Save as disclosed above, as at the date of this announcement, Dr. Wang confirmed that (i) he has not held any directorship in other public listed companies in Hong Kong or overseas in the past three years; (ii) he does not hold any other position with the Company or subsidiaries of the Company; (iii) he does not have any other major appointments or professional qualifications; (iv) he does not have any relationship with any other Directors, senior management, substantial shareholders or controlling shareholders of the Company; and (v) he does not hold any other interests in the Shares within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, the Board is not aware of any other information in relation to the appointment of Dr. Wang as an executive Director that is required to be disclosed pursuant to the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and there are no other matters in relation to the appointment of Dr. Wang as an executive Director that need to be brought to the attention of the shareholders of the Company.

By order of the Board  
**Sirnaomics Ltd.**  
**Yang (Patrick) Lu**  
*Chairman and Executive Director*

Hong Kong, May 10, 2024

*As at the date of this announcement, the Board comprises Dr. Yang Lu (alias Patrick Lu), Dr. Xiaochang Dai, Dr. David Mark Evans and Dr. Edward Yongxiang Wang as executive Directors, Mr. Mincong Huang and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Mr. Fengmao Hua, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.*